Jill DeSimone - 24 Jun 2026 Form 4 Insider Report for Praxis Precision Medicines, Inc. (PRAX)

Reporting relationship: Director
Issuer ticker: PRAX
Reported as of: 24 Jun 2026
Net transaction value: -$3,611,335
SEC form: 4
Accepted by SEC: 26 Jun 2026, 17:09:23 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Alex Nemiroff, as Attorney-in-Fact

Key filing fact

Jill DeSimone filed Form 4 for Praxis Precision Medicines, Inc. (PRAX) on 26 Jun 2026.

Key facts

This page summarizes Jill DeSimone's Form 4 filing for Praxis Precision Medicines, Inc. (PRAX).
16 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 26 Jun 2026, 17:09.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: -$3,611,335.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001930479 Primary reporting owner

DeSimone Jill

Relationship: Director
Address: C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON
Signature: /s/ Alex Nemiroff, as Attorney-in-Fact
Signature date: 26 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PRAX transaction

Common Stock

Options Exercise

Transaction value
Shares: +8,566
Change %: +367%
Price: $44.25^*
Shares after: 10,903
Date: 24 Jun 2026
Ownership: Direct

PRAX transaction

Common Stock

Options Exercise

Transaction value
Shares: +3,034
Change %: +28%
Price: $147.30^*
Shares after: 13,937
Date: 24 Jun 2026
Ownership: Direct

PRAX transaction

Common Stock

Sale

Transaction value: $3,014
Shares: -10
Change %: -0.07%
Price: $301.44
Shares after: 13,927
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1

PRAX transaction

Common Stock

Sale

Transaction value: $36,375
Shares: -120
Change %: -0.86%
Price: $303.13
Shares after: 13,807
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F2

PRAX transaction

Common Stock

Sale

Transaction value: $97,699
Shares: -320
Change %: -2.3%
Price: $305.31
Shares after: 13,487
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F3

PRAX transaction

Common Stock

Sale

Transaction value: $209,522
Shares: -683
Change %: -5.1%
Price: $306.77
Shares after: 12,804
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F4

PRAX transaction

Common Stock

Sale

Transaction value: $382,221
Shares: -1,240
Change %: -9.7%
Price: $308.24
Shares after: 11,564
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F5

PRAX transaction

Common Stock

Sale

Transaction value: $309,074
Shares: -999
Change %: -8.6%
Price: $309.38
Shares after: 10,565
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F6

PRAX transaction

Common Stock

Sale

Transaction value: $544,056
Shares: -1,750
Change %: -17%
Price: $310.89
Shares after: 8,815
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F7

PRAX transaction

Common Stock

Sale

Transaction value: $890,203
Shares: -2,854
Change %: -32%
Price: $311.91
Shares after: 5,961
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F8

PRAX transaction

Common Stock

Sale

Transaction value: $314,081
Shares: -1,004
Change %: -17%
Price: $312.83
Shares after: 4,957
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F9

PRAX transaction

Common Stock

Sale

Transaction value: $158,086
Shares: -504
Change %: -10%
Price: $313.66
Shares after: 4,453
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F10

PRAX transaction

Common Stock

Sale

Transaction value: $402,758
Shares: -1,279
Change %: -29%
Price: $314.90
Shares after: 3,174
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F11

PRAX transaction

Common Stock

Sale

Transaction value: $264,245
Shares: -837
Change %: -26%
Price: $315.70
Shares after: 2,337
Date: 24 Jun 2026
Ownership: Direct
Footnotes: F1, F12

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PRAX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -8,566
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 24 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,566
Exercise price: $44.25
Footnotes: F13

PRAX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -3,034
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 24 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,034
Exercise price: $147.30
Footnotes: F14

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 14 footnotes

Footnote F1

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 25, 2026.

Footnote F2

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $302.500 to $303.440. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Footnote F3

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $305.000 to $305.830. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Footnote F4

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $306.365 to $307.180. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Footnote F5

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $307.900 to $308.870. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Footnote F6

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $308.900 to $309.790. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Footnote F7

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $310.340 to $311.300. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Footnote F8

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $311.340 to $312.320. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Footnote F9

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $312.370 to $313.280. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Footnote F10

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $313.400 to $314.000. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Footnote F11

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $314.400 to $315.380. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Footnote F12

The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $315.590 to $316.010. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

Footnote F13

This option was fully vested as of June 5, 2025.

Footnote F14

This option was fully vested as of May 23, 2025.